Skip to main content

Hugel

Hugel Inc is a South Korean multinational biopharmaceutical and medical aesthetics company specializing in the research, development, and manufacturing of botulinum toxin products, hyaluronic acid dermal fillers, and therapeutic pharmaceutical formulations. The company produces high-purity botulinum toxin type A products (marketed under brands like Botulax) and medical aesthetic solutions supplied to dermatologists, plastic surgeons, and medical clinics across South Korea and international export markets. Its core business operations encompass biopharmaceutical research, sterile toxin manufacturing, aesthetic product formulation, and global wholesale distribution. Revenue is derived directly from the global wholesale sale of medical aesthetic products and pharmaceuticals to healthcare distributors. Hugel holds a leading market position in botulinum toxin manufacturing and aesthetic medicine in South Korea. The company is headquartered in Chuncheon, South Korea, and its shares trade on the Korea Exchange.

7 of the funds FundTelligence covers report a position in Hugel.

Legal name
HUGEL INC
Sector
Health Care
Country
South Korea
Funds holding it
7

Funds holding Hugel

Loading...